Trial · NCT07034950
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | thermal ablation-induced somatic responses to pain | Day 1 (During the surgery at the first stage of the research) | Positive: Body movement or complaint of pain. Negative: No body movement or no reported pain. This scale will be administered during the surgery at the first stage of the research. |
| Primary | Incidence of respiratory depression | Day 1 (T2-T5 of the second stage of the research) | By comparing with the control group, evaluate the safety of ED95 of esketamine by the incidence of respiratory depression at T2-T5 of the second stage of the research. The primary outcome is the incidence of respiratory depression, which is defined as SpO2 \<90% or EtCO2 \>55 mmHg. T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU. |
| Secondary | HR | Day 1 (T1-T5 of the first and second stages of the research) | HR: heart rate. T1: Prior to anesthesia (10 minutes after positioning); T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU. |
| Secondary | MAP | Day 1 (T1-T5 of the first and second stages of the research) | MAP: Mean Arterial Pressure. T1: Prior to anesthesia (10 minutes after positioning); T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU. |
| Secondary | RR | Day 1 (T1-T5 of the first and second stages of the research) | RR: respiratory rate. T1: Prior to anesthesia (10 minutes after positioning); T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU. |
| Secondary | SPO2 | Day 1 (T1-T5 of the first and second stages of the research) | SPO2: peripheral oxygen saturation. T1: Prior to anesthesia (10 minutes after positioning); T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU. |
| Secondary | EtCO2 | Day 1 (T2-T5 of the first and second stages of the research) | EtCO2: End-expiratory carbon dioxide. T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; and T5: In the PACU. |
| Secondary | Adverse events | Day 1 (T2-T8 of the first and second stages of the research) | Adverse events will encompass a range of systems, including the cardiovascular system (eg. high/low blood pressure and sinus tachycardia/bradycardia), as well as symptoms such as nausea, vomiting, dizziness, and mental symptoms. T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors; T5: In the PACU. T6 to T8: 2, 6, and 24 hours after the procedure. |
| Secondary | NRS | Day 1 (T6-T8 of the first and second stages of the research) | The Numeric Rating Scale (NRS) will be utilized to assess postoperative pain, with a range of 0 representing no pain and 10 representing severe pain. This scale will be administered at 2, 6, and 24 hours following the procedure. T6 to T8: 2, 6, and 24 hours after the procedure. |
| Secondary | The need for remedial analgesia | Day 1 (T6-T8 of the first and second stages of the research) | The consumption of remedial analgesia will be the total consumption of acetaminophen documented at 2, 6, and 24 hours after the procedure. T6 to T8: 2, 6, and 24 hours after the procedure. |
| Secondary | Success rate of anesthesia | Day 1 (T2-T4 of the second stage of the research) | Anesthesia success will be defined as inadequate analgesia requiring ≤3 rescue doses of remifentanil within 10 min throughout the procedure. The success rate of anesthesia will be calculated by dividing the number of successful anesthesia cases by the total number of cases. T2: 60 seconds after esketamine injection; T3: 5 minutes after HHNB; T4: During thermal ablation of liver tumors |
| Secondary | Induction duration | Day 1 of the second stage of the research | Induction duration is defined as the period from the start of anaesthetic drug injection to the commencement of the surgical procedure at the second stage of the research. |
| Secondary | Duration of awakening | Day 1 of the second stage of the research | Duration of awakening is defined as the period from the conclusion of the surgical procedure to the moment of eye-opening. |
| Secondary | Duration of stay in the hospital | Day 1 and Day 2 of the second stage of the research | Duration of stay in the hospital is measured from the moment the patient enters the operating room until the moment they are discharged. |
| Secondary | The satisfaction of the sonographer | Day 1 of the second stage of the research | The satisfaction score of the sonographer will be collected postoperatively on Day 1, using a scale ranging from 0 to 10, with 0 representing dissatisfaction and 10 representing very satisfied. |
| Secondary | The satisfaction of patients | Day 2 of the second stage of the research | The satisfaction of patients will be collected postoperatively on Day 2, using a scale ranging from 0 to 10, with 0 representing dissatisfaction and 10 representing very satisfied. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07034950/registered